Given the insights into the sexual disparity in cachexia (discussed further in the text) and the tumor immune infiltration related to IL-6 signaling, it will be important to pay attention to the sex-segregated analysis of IL-6/STAT3 modulation in PDAC, especially as there is an ongoing clinical trial for combined MEK, STAT3, and PD-1 inhibition in metastatic PDAC (NCT05440942). This evidence concerns the gene MAP2K7 and neoplasm.